A Review of the Rational and Current Evidence on Colchicine for COVID-19

被引:2
|
作者
Ghaith, Hazem S. [1 ]
Gabra, Mohamed Diaa [2 ]
Nafady, Mohamed H. [3 ]
Elshawah, Hamza Emad [4 ]
Negida, Ahmed [5 ,6 ]
Mushtaq, Gohar [7 ]
Kamal, Mohammad Amjad [8 ,9 ,10 ,11 ]
机构
[1] Al Azhar Univ, Fac Med, Cairo, Egypt
[2] South Valley Univ, Fac Med, Qena, Egypt
[3] Misr Univ Sci & Technol, Fac Appl Med Sci, 6th October City, Egypt
[4] Al Azhar Univ, Fac Med, New Damietta, Egypt
[5] Zagazig Univ, Fac Med, Zagazig, Egypt
[6] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth, England
[7] Idlib Univ, Fac Med, Ctr Sci Res, Idlib, Syria
[8] Sichuan Univ, West China Hosp, Inst Syst Genet, Frontiers Sci Ctr Dis Related Mol Network, Chengdu, Peoples R China
[9] King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah 21589, Saudi Arabia
[10] Daffodil Int Univ, Fac Allied Hlth Sci, Dept Pharm, Dhaka 1207, Bangladesh
[11] Enzymoics, Novel Global Community Educ Fdn, 7 Peterlee Pl, Hebersham, NSW 2770, Australia
关键词
Anti-inflammatory agents; immunosuppressive agents; immune modulators; colchicine; COVID-19; SARS-CoV-2; CORONAVIRUS; PROTEIN; ACE2;
D O I
10.2174/1381612827666211210142352
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The current coronavirus disease (COVID-19) pandemic has affected millions of individuals worldwide. Despite extensive research efforts, few therapeutic options currently offer direct clinical benefits for COVID-19 patients. Despite the advances in our understanding of COVID-19, the mortality rates remain significantly high owing to the high viral transmission rates in several countries and the rise of various mutations in the SARS-CoV-2. One currently available and widely used drug that combines both anti-inflammatory and immunomodulatory actions is colchicine, which has been proposed as a possible treatment option for COVID-19. Colchicine still did not get much attention from the medical and scientific communities despite its anti-inflammatory and immunomodulatory mechanisms of action and positive preliminary data from early trials. This literature review article provides the scientific rationale for repurposing colchicine as a potential therapy for COVID-19. Further, we summarize colchicine's mechanisms of action and possible roles in COVID-19 patients. Finally, we supplement this review with a summary of the doses, side effects, and early efficacy data from clinical trials to date. Despite the promising early findings from multiple observational and clinical trials about the potential of colchicine in COVID-19, the data from the RECOVERY trial, the largest COVID-19 randomized controlled trial (RCT) in the world, showed no evidence of clinical benefits in mortality, hospital stays, or disease progression (n = 11340 patients). However, multiple other smaller clinical trials showed significant clinical benefits. We conclude that while current evidence does not support the use of colchicine for treating COVID-19, the present body of evidence is heterogeneous and inconclusive. The drug cannot be used in clinical practice or abandoned from clinical research without additional large RCTs providing more robust evidence. At present, the drug should not be used except for investigational purposes.
引用
收藏
页码:3194 / 3201
页数:8
相关论文
共 50 条
  • [31] Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
    Brunetti, Luigi
    Diawara, Oumou
    Tsai, Andrew
    Firestein, Bonnie L.
    Nahass, Ronald G.
    Poiani, George
    Schlesinger, Naomi
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) : 1 - 12
  • [32] COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology
    Magro, Fernando
    Nuzzo, Alexandre
    Abreu, Candida
    Libanio, Diogo
    Rodriguez-Lago, Iago
    Pawlak, Katarzyna
    Hollenbach, Marcus
    Brouwer, Willem P.
    Siau, Keith
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2021, 9 (07) : 750 - 765
  • [33] The role of telehealth during COVID-19 outbreak: a systematic review based on current evidence
    Elham Monaghesh
    Alireza Hajizadeh
    BMC Public Health, 20
  • [34] Comprehensive overview of COVID-19 based on current evidence
    Kang, Yue
    Xu, Silu
    DERMATOLOGIC THERAPY, 2020, 33 (05)
  • [35] The role of telehealth during COVID-19 outbreak: a systematic review based on current evidence
    Monaghesh, Elham
    Hajizadeh, Alireza
    BMC PUBLIC HEALTH, 2020, 20 (01)
  • [36] Current evidence on COVID-19 and coagulopathy
    Cecere, Domenico
    Cappello, Enrico
    Izzo, Marcello
    Pompeo, Francesco
    ITALIAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2022, 29 (01): : 28 - 33
  • [37] Invited Review: The spectrum of neuropathology in COVID-19
    Al-Sarraj, S.
    Troakes, C.
    Hanley, B.
    Osborn, M.
    Richardson, M. P.
    Hotopf, M.
    Bullmore, E.
    Everall, I. P.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2021, 47 (01) : 3 - 16
  • [38] Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence
    Kumric, Marko
    Kurir, Tina Ticinovic
    Martinovic, Dinko
    Zivkovic, Piero Marin
    Bozic, Josko
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (25) : 3748 - 3761
  • [39] Telemedicine in the COVID-19 Era: A Narrative Review Based on Current Evidence
    Nittari, Giulio
    Savva, Demetris
    Tomassoni, Daniele
    Tayebati, Seyed Khosrow
    Amenta, Francesco
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (09)
  • [40] COVID-19, colchicine and glycemia
    Ilias, Ioannis
    Milionis, Charalambos
    MEDICAL HYPOTHESES, 2021, 149